Healthcare Companies Seek Innovative Ways to Combat New Diseases

Tuesday, October 1, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

NEW YORK, Oct. 1, 2019 /PRNewswire/ -- Many underdeveloped regions around the world are ravaged by diseases due to their lack of proper healthcare. And despite ongoing medical advancements, researchers have noted that new diseases are continuing to emerge. The Institute for Health Metrics and Evaluation (IHME) highlighted

in a report that between 1950 and 2017, there were a total of 359 new diseases and injuries added to the fatal and non-fatal list of conditions. Some of the most common cases include cancer, heart conditions, stroke, respiratory infections, lung diseases, Alzheimer's, diabetes, and kidney diseases. And while a handful of these conditions are unpreventable or incurable, some can be treated or slowed with the use of innovative medicines. For instance, cancer patients typically undergo chemotherapy or radiotherapy as both treatments are aimed at controlling or potentially eliminating cancerous cells. On the other hand, medicines as simple as vitamin C supplements can significantly boost the body's immune system. And while there are many treatments aimed towards eliminating bacteria or infection within the human body, many medical personnel also highly recommend maintaining a strong immune system, which is the natural defense against infections and diseases. Generally, a weakened immune system increases the likelihood of contracting a disease. However, on a larger-scale, researchers believe that a weak immune system can increase the possibility of cancer development as well. According to data compiled by Zion Market Research, the global immunotherapy drugs market was valued at approximately USD 138.4 Billion in 2018. By 2025, the market is expected to reach USD 330.4 Billion while accelerating at a CAGR of 13.24% between the forecast period from 2019 to 2025. INmune Bio, Inc. (NASDAQ: INMB), Eli Lilly and Company (NYSE: LLY), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NYSE: AZN)

Immunotherapy, also referred to as biological therapy, uses the body's natural defense system to fight against cancerous cells and other infections. Typically, drugs used in immunotherapy either suppress or enhance the body's immune system. And while immunotherapy isn't as popular as chemotherapy or radiotherapy, it is believed that it offers fewer side effects as it uses the body's natural defense mechanism. Researchers also believe that immunotherapy could become a promising treatment option for complex disorders such as cancer and autoimmune diseases. Overall, there are several types of immunotherapies for cancer treatment, such as monoclonal antibodies, oncolytic virus therapy, T-cell therapies, and cancer vaccines. Furthermore, it is also believed that immunotherapy drugs can effectively treat autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, according to the National Cancer Institute. And while immunotherapy is generally believed to be much safer than chemotherapy, medical experts have noted that there is not enough research within the sector to be certain. Hussein Tawbi, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, mentioned that having an overactive immune system is the main reason why patients with both cancer and autoimmune diseases have not been included in clinical trials for immunotherapy diseases. Tawbi noted that for many doctors who treat patients with both diseases, the lack of information on the effects of immunotherapy has led to a "clinical conundrum." Nonetheless, as research continues to develop within the immunotherapy market, the sector's growth is positioned to outpace the growth rate of the chemotherapy and radiotherapy markets. "As an oncologist, nothing makes me happier than to find a therapy that works for one of my patients – something that halts that patient's cancer in its tracks," said Leon Hwang, M.D., board-certified Medical Oncologist with the Mid-Atlantic Permanente Medical Group in Washington D.C. "So I am particularly excited by recent advances in immunotherapy, a medical strategy that enlists the patient's own body to recognize and fight off deadly types of cancer. Advances in immunotherapy are proceeding at an amazing pace, and today I have patients who are living three and four times longer than we ever could have hoped, and with minimal side effects, thanks to this type of treatment."

INmune Bio, Inc. (NASDAQ: INMB) announced earlier last week that, "RJ Tesi, M.D., Co-Founder and CEO will be featured in an interview with multimedia financial reporter, Jason Lin discussing the company's accomplishments. The interview can be found by clicking here (

'Nasdaq's MarketSite is a premiere platform for INmune Bio to share our story with investors and to discuss recent developments in our programs for cancer, Alzheimer's disease and nonalcoholic steatohepatitis (NASH) liver disease,' said Dr. Tesi. 'We hope to continue reaching new milestones in the development of therapies that target the innate immune system.'

INmune Bio has four drug development programs: two that are designed to treat cancer, INKmune™ and INB03 — with recently reported positive preliminary data from the Phase 1 trial in patients with advanced cancer; XPro1595 for the treatment of neuroinflammation and Alzheimer's disease; and NeuLiv™ for the treatment of NASH.

Additionally, CJ Barnum, Ph.D., Director of Neuroscience, will present on "Approaching Alzheimer's disease as an immunological disease: role of biomarkers" at the World Immunotherapy Congress on Oct. 16 in Switzerland.

About INmune Bio, Inc: INmune Bio, Inc.  is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms.  The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for cancer (INB03), Alzheimer's (XPro595), and NASH (NeuLiv). The Innate Immune Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer.  INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit"

Eli Lilly and Company (NYSE: LLY) is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. Eli Lilly and Company recently announced Verzenio® (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer previously treated with endocrine therapy (median of 46.7 months vs. median of 37.3 months with placebo plus fulvestrant; HR: 0.757; 95% CI: 0.606, 0.945; P = 0.0137). Results from the Phase 3 MONARCH 2 clinical trial, which included both pre/peri- and postmenopausal women, were consistent across subgroups. These results were presented as a late-breaking abstract in the Presidential Symposium at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain and simultaneously published in JAMA Oncology. "When patients receive a diagnosis of advanced breast cancer, they learn that their disease is treatable, but incurable. This is devastating news to those of us living with the disease, because we each have a lot more living to do with our loved ones and friends and goals we want to achieve. We patients want therapies that can result in longer life," said Shirley Mertz, President of the Metastatic Breast Cancer Network. "Hearing that the results of MONARCH 2 showed significant improvement in overall survival for women living with HR+, HER2- advanced breast cancer is exciting and welcomed. Women with this type of breast cancer now have a treatment option that may allow them more time to achieve their dreams."

Bristol-Myers Squibb Company (NYSE: BMY) is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. recently announced results from the Phase 3 ATTRACTION-3 trial evaluating Opdivo (nivolumab) versus chemotherapy (docetaxel or paclitaxel) for the treatment of patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs. For the primary endpoint of overall survival (OS), Opdivo demonstrated a statistically significant improvement over chemotherapy, with a 23% reduction in risk of death [Hazard Ratio (HR) 0.77; 95% Confidence Interval (CI): 0.62 to 0.96; p=0.019] and a 2.5-month improvement in median OS [10.9 months (95% CI: 9.2 to 13.3)] compared to patients treated with chemotherapy [8.4 months (95% CI: 7.2 to 9.9)]. The safety profile of Opdivo in this trial was consistent with previously reported studies in ESCC and other solid tumors. Patients treated in the Opdivo arm showed 12- and 18-month OS rates of 47% (95% CI: 40 to 54) and 31% (95% CI: 24 to 37), respectively, versus 34% (95% CI: 28 to 41) and 21% (95% CI: 15 to 27) among patients in the chemotherapy arm. Survival benefit with Opdivo was observed regardless of tumor PD-L1 expression levels. An exploratory analysis of patient-reported outcomes showed significant overall improvement in quality of life with Opdivo versus chemotherapy. "The significant survival benefit coupled with the favorable safety profile and patient-reported outcomes observed in this trial suggest Opdivo has the potential to represent an important new second-line treatment option for patients with advanced esophageal squamous cell carcinoma, offering the possibility to extend their survival and improve their quality of life during treatment," said Dr. Byoung Chul Cho, Professor, Yonsei Cancer Center, Yonsei University College of Medicine.

GlaxoSmithKline plc (NYSE; GSK) is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. GlaxoSmithKline plc recently announced positive results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomized, double-blind, placebo-controlled, study of ZEJULA (niraparib) as a maintenance therapy in patients with first-line ovarian cancer following platinum-based chemotherapy. The study met its primary endpoint of a statistically significant improvement in progression-free survival for women regardless of their biomarker status. Dr Hal Barron, Chief Scientific Officer and President, R&D, GSK, said: "Almost 300,000 women around the world are diagnosed with ovarian cancer every year, yet only about 15% of patients are currently eligible to receive PARP inhibitors as their initial therapy. These exciting data demonstrate that ZEJULA has the potential to significantly benefit even more women with this devastating cancer."

AstraZeneca PLC (NYSE: AZN) has a deep-rooted heritage in oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients' lives and the Company's future. AstraZeneca unveiled a series of breakthrough data across multiple cancer types in its mission to one day eliminate cancer as a cause of death at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, 27th of September to the 1st of October 2019. With 63 abstracts, including 7 oral presentations, the Company will demonstrate its leadership in precision medicine and immunotherapy. Dave Fredrickson, Executive Vice President, Oncology, said: "The practice-changing data we are presenting at ESMO 2019 demonstrates our commitment to make prolonged survival a realistic outcome. By using biomarkers to define optimal treatment and match innovative precision medicines to the patients who can best benefit from them, our dynamic Oncology pipeline and pioneering research continue to deliver new potential medicines across multiple deadly cancers."

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For INmune Bio, Inc. financial and corporate news dissemination, has been compensated five thousand dollars by world wide holdings. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further information:

Media Contact: +1-877-601-1879


Cision View original content:


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store